Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer-Reference-Cited by-同舟云学术

Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer

Published:2020-03 Issue: Volume:144 Page:101-104
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Shaverdian Narek,Offin Michael D.,Rimner Andreas^ORCID,Shepherd Annemarie F.,Wu Abraham J.^ORCID,Rudin Charles M.,Hellmann Matthew D.,Chaft Jamie E.,Gomez Daniel R.^ORCID

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology

Reference11 articles.

1. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

2. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology;Hanna;J Clin Oncol,2008

3. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04;Ahn;J Clin Oncol,2015

4. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N Engl J Med,2017

5. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy;BMC Cancer;2024-02-23

2. Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT);Journal of Clinical Oncology;2023-11-21

3. Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer;Clinical and Translational Radiation Oncology;2023-07

4. Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System;Clinical Lung Cancer;2023-07

5. Locally Advanced Lung Cancer;Hematology/Oncology Clinics of North America;2023-06